E-Learning

Australia's corporate regulator said on Tuesday the country's stock market operator would be required to publish a comparison of clearing and settlement fees against foreign providers and justify any fee increases, in a bid to promote competition. The Australian Securities and Investments Commission (ASIC) said ASX, responsible for some A$5 billion ($3.2 billion) of trades a day, must ensure its clearing and settlement services were offered in a transparent and non-discriminatory way. "This is about limiting ASX's ability to misuse its monopoly power to deter new entrants," ASIC Chair Joe Longo said in a statement.

Tesla shares fell again Monday, extending a recent slump that has made the stock the weakest performer in the Magnificent 7 so far in 2025.

Infrastructure construction company Primoris (NYSE:PRIM) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 14.9% year on year to $1.74 billion. Its non-GAAP profit of $1.13 per share was 51.2% above analysts’ consensus estimates.

Stocks are eyeing a rebound as investors eye tariff risks to Nvidia in the countdown to its earnings

Genetic testing company Myriad Genetics (NASDAQ:MYGN) fell short of the market’s revenue expectations in Q4 CY2024, but sales rose 7.1% year on year to $210.6 million. The company’s full-year revenue guidance of $850 million at the midpoint came in 1.5% below analysts’ estimates. Its non-GAAP profit of $0.03 per share was in line with analysts’ consensus estimates.

3D measurement and imaging company FARO (NASDAQ:FARO) reported Q4 CY2024 results exceeding the market’s revenue expectations, but sales fell by 5.4% year on year to $93.54 million. The company expects next quarter’s revenue to be around $81 million, close to analysts’ estimates. Its non-GAAP profit of $0.50 per share was 25% above analysts’ consensus estimates.

Video conferencing platform Zoom (NASDAQ:ZM) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 3.3% year on year to $1.18 billion. On the other hand, next quarter’s revenue guidance of $1.16 billion was less impressive, coming in 0.8% below analysts’ estimates. Its non-GAAP profit of $1.41 per share was 4.6% above analysts’ consensus estimates.

Telehealth company Hims & Hers Health (NYSE:HIMS) announced better-than-expected revenue in Q4 CY2024, with sales up 95.1% year on year to $481.1 million. On top of that, next quarter’s revenue guidance ($530 million at the midpoint) was surprisingly good and 4.6% above what analysts were expecting. Its GAAP profit of $0.11 per share was in line with analysts’ consensus estimates.

Home healthcare provider Addus HomeCare (NASDAQ:ADUS) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 7.5% year on year to $297.1 million. Its non-GAAP profit of $1.38 per share was 1.6% above analysts’ consensus estimates.

Palantir stock extended its slide over ongoing concerns of potential Pentagon budget cuts impacting the software company's revenue.